8-KAcquisitions & Dispositions

Edwards Lifesciences Corp 8-K Report, Acquisition Completed (Aug 28, 2015)

Filed August 28, 2015For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) announced the completion of its acquisition of CardiAQ Valve Technologies, Inc. on August 26, 2015. This strategic move involved a cash payment of approximately $350 million at closing, with an additional $50 million contingent upon the achievement of a European regulatory milestone. CardiAQ, a developer of transcatheter mitral valve replacement technology, is now a wholly-owned subsidiary of Edwards. This acquisition is significant for Edwards as it bolsters its position in the rapidly growing transcatheter heart valve market, particularly in the complex mitral valve segment. The integration of CardiAQ's technology is expected to accelerate Edwards' development and commercialization efforts in this critical area, potentially leading to enhanced patient outcomes and increased market share. Investors should monitor the progress of CardiAQ's technology and the achievement of the European regulatory milestone, which will impact the total acquisition cost.

Key Highlights

  • 1Edwards Lifesciences completed the acquisition of CardiAQ Valve Technologies, Inc. on August 26, 2015.
  • 2The initial cash consideration for the acquisition was approximately $350 million.
  • 3An additional $50 million in cash is payable upon the achievement of a European regulatory milestone for CardiAQ's technology.
  • 4CardiAQ Valve Technologies specializes in transcatheter mitral valve replacement technology.
  • 5The acquisition positions Edwards to expand its offerings in the transcatheter heart valve market, specifically in the mitral valve segment.
  • 6CardiAQ will operate as a wholly-owned subsidiary of Edwards Lifesciences.
  • 7The transaction was structured as a merger where CardiAQ is the surviving entity.

Frequently Asked Questions

Edwards Lifesciences acquired CardiAQ Valve Technologies to strengthen its position in the transcatheter heart valve market, particularly by acquiring advanced technology for mitral valve replacement. This move aims to accelerate the development and commercialization of solutions for mitral valve disease and enhance patient care in this critical area.

The total potential cost of the acquisition is approximately $400 million. This includes an initial cash payment of $350 million at closing and a potential additional $50 million payable if a specific European regulatory milestone is achieved.

The European regulatory milestone is crucial as it determines whether the additional $50 million in contingent consideration will be paid. Its achievement indicates the successful progression of CardiAQ's technology through the regulatory approval process in Europe, a key step for market access and commercialization.

CardiAQ Valve Technologies is developing transcatheter mitral valve replacement (TMVR) technology. This innovative approach allows for valve replacement through minimally invasive procedures, addressing a significant unmet need in the treatment of mitral valve disease.